Abstract | BACKGROUND: MATERIAL/METHODS: RESULTS: The c-erbB-2 protein expression was observed in 15 out of 17 cases (88.3%) in group I, 22 out of 25 cases (88%) cases in group II, and in 19 out of 23 cases (82.6%) in group III. There were no statistically significant differences between the examined groups. The strongest c-erbB-2 immunoexpression was observed in low grade astrocytomas (diffuse astrocytomas G2); in the glioblastoma group the c-erbB-2 protein expression was weak and 17.4% of cases were negative. CONCLUSIONS: C-erbB-2 protooncogene alteration is an early phenomenon in glial tumor development and progression.
|
Authors | Joanna Reszeć, Piotr S Bernaczyk, Robert Milewski, Lech Chyczewski, Zenon Mariak |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 17
Issue 8
Pg. BR216-220
(Aug 2011)
ISSN: 1643-3750 [Electronic] United States |
PMID | 21804458
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Astrocytoma
(metabolism, pathology)
- Brain Neoplasms
(metabolism, pathology)
- Female
- Humans
- Male
- Middle Aged
- Receptor, ErbB-2
(genetics, metabolism)
|